HIGHLIGHTS
- who: Matthew G. Holt from the Laboratory of Glia Biology, VIB-KU Leuven, Center for Brain and Disease Research, Leuven, Belgium, Department of de Investigau00e7u00e3o e Inovau00e7u00e3o em Sau00fade (i S), University of Porto, Porto, Portugal Regenxbio Inc, United States have published the research: AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System, in the Journal: (JOURNAL)
- what: The potential of AAVs as drug delivery platforms, particularly if supported by further successful outcomes in clinical trials, will undoubtedly drive research aimed at further improving and refining the technology, particularly for use in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.